A Pilot Study of Tremelimumab - A Monoclonal Antibody Against CTLA-4 in Combination With Trans-Arterial Catheter Chemoembolization (TACE), Radiofrequency Ablation (RFA), or Cryoablation in Subjects With Hepatocellular Carcinoma (HCC) or Biliary Tract Carcinomas (BTC)

Next Previous
Trial Profile

A Pilot Study of Tremelimumab - A Monoclonal Antibody Against CTLA-4 in Combination With Trans-Arterial Catheter Chemoembolization (TACE), Radiofrequency Ablation (RFA), or Cryoablation in Subjects With Hepatocellular Carcinoma (HCC) or Biliary Tract Carcinomas (BTC)

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 20 Jan 2018

At a glance

  • Drugs Tremelimumab (Primary)
  • Indications Biliary cancer; Liver cancer
  • Focus Adverse reactions

    • Most Recent Events

    • 20 Jan 2018 Results (n=20) assessing safety and feasibility in patients with refractory biliary tract cancer, presented at the 2018 Gastrointestinal Cancers Symposium.
    • 03 Jan 2018 Planned primary completion date changed from 31 Dec 2017 to 31 Dec 2018.
    • 05 Aug 2017 Planned End Date changed from 16 Oct 2017 to 31 Dec 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top